WO2005102348A1 - Composition and method of decreasing renal ischemic damage - Google Patents
Composition and method of decreasing renal ischemic damage Download PDFInfo
- Publication number
- WO2005102348A1 WO2005102348A1 PCT/US2005/013175 US2005013175W WO2005102348A1 WO 2005102348 A1 WO2005102348 A1 WO 2005102348A1 US 2005013175 W US2005013175 W US 2005013175W WO 2005102348 A1 WO2005102348 A1 WO 2005102348A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- agent
- phosphodiesterase inhibitor
- phosphodiesterase
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- kidney removal for transplantation is also associated with ischemic damage.
- ischemic damage In the United States alone, there are approximately 9,000 kidney transplants each year. Of these, approximately 500 are found to have significant ischemic damage during transplantation.
- the mechanism of renal ischemic damage is partly understood. Animal studies have demonstrated that deliberately decreasing renal blood flow and glomerular filtration rate using CO 2 pneumoperitoneum preconditioning prior to the ischemic event significantly decreases the area and amount of ischemic damage. The effect of such limited ischemic preconditioning appears to lead to an increase in nitric oxide metabolites due to an increase in endothelial nitric oxide synthase.
- the one or more than one dose of the agent is between about 2 doses and 6 doses. In another embodiment, the one or more than one dose of the agent is three doses. In one embodiment, the one or more than one dose is a plurality of doses administered between about 1 minute and 2 days apart. In another embodiment, the one or more than one dose is a plurality of doses administered between about 10 minutes and 1 day apart. In another embodiment, the one or more than one dose is a plurality of doses administered between about 30 minutes and 4 hours apart. According to another embodiment of the present invention, there is provided a composition for decreasing renal ischemic damage comprising two or more than two phosphodiesterase inhibitors.
- the two or more than two phosphodiesterase inhibitors are selected from the group consisting of a type 3 phosphodiesterase inhibitor, a type 4 phosphodiesterase inhibitor, a type 5 phosphodiesterase inhibitor and a type 9 phosphodiesterase inhibitor. In another embodiment, at least one of the two or more than two phosphodiesterase inhibitors is a type 5 phosphodiesterase inhibitor. In one embodiment, at least one of the two or more than two phosphodiesterase inhibitors is selected from the group consisting of sildenafil, tadalafil and vardenafil. In one embodiment, the amount of at least one of the two or more than two phosphodiesterase inhibitors is between about 1 mg and 1 g.
- the amount of at least one of the two or more than two phosphodiesterase inhibitors is between about 10 mg and 200 mg. In another embodiment, the amount of at least one of the two or more than two phosphodiesterase inhibitors is between about 25 mg to 100 mg. In another embodiment, the composition further comprises one or more than one substance selected from the group consisting of a binding agent, a coloring agent, an enteric coating and a flavoring agent. According to another embodiment of the present invention, there is provided a composition for decreasing renal ischemic damage comprising two or more than two HMG- CoA reductase inhibitors.
- At least one of the two or more than two HMG-CoA reductase inhibitors is selected from the group consisting of atorvastatin calcium, fluvastatin sodium, lovastatin, pitavastatin calcium, pravastatin sodium, rosuvastatin calcium and simvastatin.
- the amount of at least one of the two or more than two HMG-CoA reductase inhibitors is between about 1 mg and 1 g. In another embodiment, the amount of at least one of the two or more than two HMG-CoA reductase inhibitors is between about 10 mg and 200 mg.
- the amount of at least one of the two or more than two HMG-CoA reductase inhibitors is between about 25 mg to 100 mg.
- the composition further comprises one or more than one substance selected from the group consisting of a binding agent, a coloring agent, an enteric coating and a flavoring agent.
- a composition for decreasing renal ischemic damage comprising one or more than one phosphodiesterase inhibitor, and one or more than one HMG-CoA reductase inhibitor.
- At least one of the one or more than one HMG-CoA reductase inhibitor is selected from the group consisting of atorvastatin calcium, fluvastatin sodium, lovastatin, pitavastatin calcium, pravastatin sodium, rosuvastatin calcium and simvastatin.
- the amount of at least one of the one or more than one phosphodiesterase inhibitor is between about 1 mg and 1 g. In another embodiment, the amount of at least one of the one or more than one phosphodiesterase inhibitor is between about 10 mg and 200 mg. In another embodiment, the amount of at least one of the one or more than one phosphodiesterase inhibitor is between about 25 mg to 100 mg.
- the amount of at least one of the one or more than one HMG-CoA reductase inhibitor is between about 1 mg and 1 g. In another embodiment, the amount of at least one of the one or more than one HMG-CoA reductase inhibitor is between about 10 mg and 200 mg. In another embodiment, the amount of at least one of the one or more than one HMG-CoA reductase inhibitor is between about 25 mg to 100 mg. In another embodiment, the composition further comprises one or more than one substance selected from the group consisting of a binding agent, a coloring agent, an enteric coating and a flavoring agent.
- the term “comprise” and variations of the term, such as “comprising” and “comprises,” are not intended to exclude other additives, components, integers or steps.
- the term “organism” includes a human.
- a method of decreasing renal ischemic damage in an organism subjected to an ischemic event In one embodiment, the organism is serving as a kidney donor during renal transplantation, and the ischemie «vent is removal of the kidney for transplantation into another organism. The method comprises, first, identifying an organism having a kidney that is susceptible to renal ischemic damage from an ischemic event.
- the method comprises administering to the organism one or more than one effective dose of an agent prior to the ischemic event.
- Administering to the organism the one or more than one effective dose of the agent serves to at least partially protect the organism's kidney from damage during a subsequent ischemic event.
- the agent is a phosphodiesterase inhibitor.
- the agent is a composition comprising a phosphodiesterase inhibitor.
- the phosphodiesterase inhibitor is selected from the group consisting of a type 3 phosphodiesterase inhibitor, a type 4 phosphodiesterase inhibitor, a type 5 phosphodiesterase inhibitor and a type 9 phosphodiesterase inhibitor.
- the phosphodiesterase inhibitor is a type 5 phosphodiesterase inhibitor.
- the agent is an HMG-CoA reductase inhibitor.
- the agent is a composition comprising an HMG-CoA reductase inhibitor.
- the one or more than one HMG-CoA reductase inhibitor is selected from the group consisting of atorvastatin calcium, fluvastatin sodium, lovastatin, pitavastatin calcium, pravastatin sodium, rosuvastatin calcium and simvastatin.
- the agent is a composition comprising both one or more than one phosphodiesterase inhibitor and one or more than one HMG-CoA reductase inhibitor.
- the one or more than one phosphodiesterase inhibitor selected from the group consisting of a type 3 phosphodiesterase inhibitor, a type 4 phosphodiesterase inhibitor, a type 5 phosphodiesterase inhibitor and a type 9 phosphodiesterase inhibitor.
- the phosphodiesterase inhibitor is a type 5 phosphodiesterase inhibitor.
- the phosphodiesterase inhibitor appears to protect the organism's kidney from a subsequent ischemic event by increasing nitric oxide levels within the organism, thereby mimicking the action of limited ischemic preconditioning.
- the HMG-CoA reductase inhibitors appear to protect the organism's kidney from a subsequent ischemic event by acting as a nitric oxide donor or through the HMG-CoA reductase inhibition pathway.
- the phosphodiesterase inhibitor is selected from the group consisting of sildenafil (Viagra ® , available from Pfizer, Inc., New York, NY US), tadalafil (Cialis ® ; available from Lilly ICOS, L.L.C. Delaware, MD US) and vardenafil (Levitra ® , available from Bayer Aktiengesellschaft, Germany), though other phosphodiesterase inhibitors can be used, as will be understood by those with skill in the art with reference to this disclosure.
- the dose of the agent for an adult human is between about 1 mg and 1 g. ' In another embodiment, the dose of the agent for an adult human is between about 10 mg and 200 mg. In another embodiment, the dose of the agent for an adult human is between about 25 mg to 100 mg. In one embodiment, the organism has a body weight and the dose of the agent is between about 0.015 mg/kg body weight and 15 mg/kg body weight. In another embodiment, the organism has a body weight and the dose of the agent between about 0.15 mg/kg body weight and 3 mg/kg body weight. In another embodiment, the organism has a body weight and the dose of the agent is between about 0.5 mg/kg body weight and 1.5 mg/kg body weight.
- the agent is administered orally, though other routes of administration are also within the scope of this invention, as will be understood by those with skill in the art with reference to this disclosure including administration by a route selected from the group consisting of administration by skin patch, administration by subcutaneous injection, administration by an inhaled preparation and direct intravenous administration.
- the one or more than one dose of the agent is between about 1 dose and 10 doses.
- the one or more than one dose of the agent is between about 2 doses and 6 doses.
- the one or more than one dose of the agent is three doses.
- the one or more than one dose is a plurality of doses administered between about 1 minute and 2 days apart.
- the one or more than one dose is a plurality of doses administered between about 10 minutes and 1 day apart. In another preferred embodiment, the one or more than one dose is a plurality of doses administered between about 30 minutes and 4 hours apart.
- a composition for decreasing renal ischemic damage comprises two or more than two phosphodiesterase inhibitors. In a preferred embodiment, the phosphodiesterase inhibitors are selected from the group consisting of a type 3 phosphodiesterase inhibitor, a type 4 phosphodiesterase inhibitor, a type 5 phosphodiesterase inhibitor and a type 9 phosphodiesterase inhibitor.
- the phosphodiesterase inhibitor is selected from the group consisting of sildenafil, tadalafil and vardenafil.
- the composition comprises two or more than two HMG- CoA reductase inhibitors.
- the HMG-CoA reductase inhibitors are selected from the group consisting of atorvastatin calcium, fluvastatin sodium, lovastatin, pitavastatin calcium, pravastatin sodium, rosuvastatin calcium and simvastatin.
- the composition of the present invention can also comprise one or more than one additional substance, such a binding agent, a coloring agent, an enteric coating and a flavoring agent.
- the composition is preferably configured to be administered orally, however, it can also be configured to be administered by skin patch, subcutaneous injection, inhaled preparations or direct intravenous administration, among other routes, as will be understood by those with skill in the art with reference to this disclosure.
- EXAMPLE I METHOD OF DECREASING RENAL ISCHEMIC DAMAGE DURING TRANSPLANTATION
- the method of the present invention can be used as follows.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005235306A AU2005235306B2 (en) | 2004-04-19 | 2005-04-18 | Composition and method of decreasing renal ischemic damage |
EP05737742A EP1737465A4 (en) | 2004-04-19 | 2005-04-18 | Composition and method of decreasing renal ischemic damage |
CA2563693A CA2563693C (en) | 2004-04-19 | 2005-04-18 | Composition and method of decreasing renal ischemic damage |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56377204P | 2004-04-19 | 2004-04-19 | |
US60/563,772 | 2004-04-19 | ||
US57853104P | 2004-06-09 | 2004-06-09 | |
US60/578,531 | 2004-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005102348A1 true WO2005102348A1 (en) | 2005-11-03 |
Family
ID=35196731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/013175 WO2005102348A1 (en) | 2004-04-19 | 2005-04-18 | Composition and method of decreasing renal ischemic damage |
Country Status (5)
Country | Link |
---|---|
US (3) | US20050234068A1 (en) |
EP (1) | EP1737465A4 (en) |
AU (2) | AU2005235306B2 (en) |
CA (1) | CA2563693C (en) |
WO (1) | WO2005102348A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012070040A1 (en) * | 2010-11-26 | 2012-05-31 | Technion Research And Development Foundation Ltd | Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2363130B1 (en) | 2006-07-05 | 2014-05-07 | Takeda GmbH | Combination of HMG-CoA reductase inhibitors atorvastatin or simvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast for the treatment of inflammatory pulmonary diseases |
KR102301639B1 (en) * | 2015-01-23 | 2021-09-14 | 삼성전자주식회사 | SoC, METHOD FOR MANAGING POWER OF THEREOF AND ELECTRONIC DEVICE |
EP3575811A1 (en) | 2018-05-28 | 2019-12-04 | Koninklijke Philips N.V. | Optical detection of a communication request by a subject being imaged in the magnetic resonance imaging system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4415556A (en) * | 1980-12-23 | 1983-11-15 | Dr. Franz Kohler Chemie Gmbh | Protective solution for heart and kidney and process for its preparation |
US20030139429A1 (en) * | 2001-09-27 | 2003-07-24 | Cohen David Saul | Combinations |
US20030181461A1 (en) * | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292658A (en) * | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
JPH11515025A (en) * | 1995-11-02 | 1999-12-21 | ワーナー−ランバート・コンパニー | Methods and pharmaceutical compositions for regulating lipid concentration |
DE19944161A1 (en) * | 1999-09-15 | 2001-03-22 | Bayer Ag | New combination for the treatment of sexual dysfunction |
US6689807B1 (en) * | 2000-06-08 | 2004-02-10 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | HMG CoA reductase inhibitors for promoting angiogenesis |
LV12978B (en) * | 2001-09-07 | 2003-05-20 | Ivars Kalvins | Pharmaceutical composition |
US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
ITMI20021012A1 (en) * | 2002-05-13 | 2003-11-13 | Giovanni Scaramuzzino | COMBINATION OF AN HMG-COA REDUCTASE INHIBITOR AND AN ESTER NITRATE |
AU2003265239A1 (en) * | 2002-05-22 | 2003-12-19 | Virginia Commonwealth University | Protective effects of pde-5 inhibitors |
BRPI0408500A (en) * | 2003-03-17 | 2006-03-07 | Pfizer Prod Inc | Type 1 diabetes treatment with pde5 inhibitors |
US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
-
2005
- 2005-04-18 EP EP05737742A patent/EP1737465A4/en not_active Withdrawn
- 2005-04-18 US US11/108,917 patent/US20050234068A1/en not_active Abandoned
- 2005-04-18 CA CA2563693A patent/CA2563693C/en not_active Expired - Fee Related
- 2005-04-18 AU AU2005235306A patent/AU2005235306B2/en not_active Ceased
- 2005-04-18 WO PCT/US2005/013175 patent/WO2005102348A1/en active Application Filing
-
2008
- 2008-08-01 US US12/185,014 patent/US20080293729A1/en not_active Abandoned
- 2008-11-07 AU AU2008243175A patent/AU2008243175A1/en not_active Abandoned
-
2011
- 2011-08-04 US US13/198,603 patent/US20120015949A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4415556A (en) * | 1980-12-23 | 1983-11-15 | Dr. Franz Kohler Chemie Gmbh | Protective solution for heart and kidney and process for its preparation |
US20030139429A1 (en) * | 2001-09-27 | 2003-07-24 | Cohen David Saul | Combinations |
US20030181461A1 (en) * | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
Non-Patent Citations (1)
Title |
---|
See also references of EP1737465A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012070040A1 (en) * | 2010-11-26 | 2012-05-31 | Technion Research And Development Foundation Ltd | Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury |
Also Published As
Publication number | Publication date |
---|---|
EP1737465A4 (en) | 2007-10-03 |
AU2008243175A1 (en) | 2008-12-04 |
AU2005235306A1 (en) | 2005-11-03 |
CA2563693C (en) | 2010-07-06 |
AU2005235306B2 (en) | 2008-08-21 |
CA2563693A1 (en) | 2005-11-03 |
US20050234068A1 (en) | 2005-10-20 |
US20120015949A1 (en) | 2012-01-19 |
US20080293729A1 (en) | 2008-11-27 |
EP1737465A1 (en) | 2007-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2401658C2 (en) | Heterocyclic aspartylprotease inhibitors | |
AU2006320162B2 (en) | Use of high-dose oxazaphosphorine drugs for treating immune disorders | |
US7776354B2 (en) | Remedies for glomerular diseases | |
US20120015949A1 (en) | Composition and method of decreasing renal ischemic damage | |
WO2007081974A2 (en) | Viral hepatitis treatment | |
IE911780A1 (en) | Method for preventing onset of restenosis after angioplasty¹employing an ace inhibitor | |
EP1213026A4 (en) | Brain cell or nerve cell protecting agents comprising ginseng | |
JP2023519158A (en) | antiviral compound | |
BG108221A (en) | Reconstitutable parenteral composition containing a cox-2 inhibitor | |
FR3095755A1 (en) | New cytoprotective drugs | |
US9034310B2 (en) | Interferon-statin combination cancer therapy | |
CA2170222A1 (en) | Use of quinoxalines in combination with protease inhibitors as medicaments for treating aids and/or hiv infections | |
RU2334517C2 (en) | Remedy potentiating anti-tumour effect, and anti-tumour remedy | |
US20090082371A1 (en) | Treatment of Viral Disease and Cancer With Nf-kappaB Inhibitors | |
KR20080015789A (en) | Novel triglyceride reducing agent | |
CA2372850A1 (en) | Synergistic combination comprising roflumilast and a pde-3 inhibitor | |
US4452794A (en) | Medicine having transplant rejection and/or immunological inflammation inhibiting activities, as well as a method for inhibiting transplant rejection and/or immunological inflammation | |
JPWO2002030425A1 (en) | Diabetes complication prevention / treatment agent | |
AU5158000A (en) | Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection | |
JP2002518448A (en) | Compositions and methods for treating high blood cholesterol | |
US20100204249A1 (en) | Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia | |
Pakyz et al. | Adverse drug events complicate antifungal therapy for pulmonary aspergilloma | |
WO2005058310A3 (en) | Use of stating for the treatment of metabolic syndrome | |
CN107428707A (en) | The amine of 4 (methoxyphenyl of 4 fluorine 2) N { 3 [(S methylsulfinyls imido grpup) methyl] phenyl } 1,3,5 triazine 2 is used for the purposes for treating Huppert's disease | |
KR20130137623A (en) | Prophylactic and/or therapeutic agent lymphedema |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2563693 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005235306 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005737742 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005235306 Country of ref document: AU Date of ref document: 20050418 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005235306 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005737742 Country of ref document: EP |